COMMUNIQUÉS West-GlobeNewswire

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
16/05/2024
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, [...]
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
15/05/2024
Reported Full Year 2023 total revenues of 2% growth at €48.5 million Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF [...]
Range Impact Reports 1Q 2024 Financial Results
15/05/2024
CLEVELAND, OHIO, May 15, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, reported [...]
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
15/05/2024
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results [...]
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
15/05/2024
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
15/05/2024
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science [...]
Extendicare Announces 2024 First Quarter Results
15/05/2024
MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2024. Results are presented in Canadian dollars [...]
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/05/2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering [...]
Profound Medical Annual General Meeting of Shareholders Voting Results
15/05/2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was [...]
Quipt Home Medical Reports Second Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 10% and Adjusted EBITDA Growth of 14%
15/05/2024
• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to Quarter End CINCINNATI, May 15, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) ( [...]
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
15/05/2024
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization [...]
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
15/05/2024
IND clearance for GTB-3650, a 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia expected in Q2 2024 Phase 1 trial initiation with GTB-3650 expected in 2H 2024 Anticipate IND submission for GTB-5550 TriKE [...]
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
15/05/2024
MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
FibroBiologics Announces 2024 Annual Meeting of Stockholders
15/05/2024
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of [...]
Precision Optics Reports Third Quarter Fiscal Year 2024 Financial Results
15/05/2024
Conference Call Scheduled for today, May 15, 2024, at 5:00pm ET GARDNER, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical [...]
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
15/05/2024
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
15/05/2024
ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR [...]
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15/05/2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies [...]
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
15/05/2024
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug [...]

Pages